PISA, A novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situ

Lubbers, Laura S.; Rowe, Blake A.; Hodge, Lisa; Browne, Susan; Gundersdorf, Richard; Jones, Philip; Hess, Fred; Reynolds, Ian J.

doi:10.1016/j.vascn.2010.01.012

Cited by 2 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies report methods to identify tumors with non-germline HRR defects: gene expression profiling, methylation-specific arrays, immunohistochemistry analysis of tissue microarrays and copy number aberrations by array comparative genomic hybridization. [117][118][119][120][121] Immunohistochemistry analysis of formalin-fixed, paraffin-embedded samples may be a useful tool for identifying DDR defects in order to stratify patients. To measure the effect of an agent that directly causes DNA DSBs in all phases of the cell cycle, patient-derived lymphocytes can be used [122].…”

Section: Predictive Biomarkersmentioning

confidence: 99%

DNA Repair and Chemotherapy

Sato¹,

Itamochi²

2015

Advances in DNA Repair

View full text Add to dashboard Cite

Section: Predictive Biomarkersmentioning

confidence: 99%

DNA Repair and Chemotherapy

Sato¹,

Itamochi²

2015

Advances in DNA Repair

View full text Add to dashboard Cite

“…In multiple clinical trials, PARP activity in peripheral mononuclear blood cells (measured as cellular levels of poly[ADP]-ribose polymers detected by immunofluorescence or enzyme-linked immunosorbent assay) has been used as a marker of effective inhibition 149,150. Surrogate markers, such as comet assay assessment of DNA damage level, or DSB estimation by RAD51 or γH2AX foci after treatment, have also been used 151.…”

Section: Synthetic Lethalitymentioning

confidence: 99%

DNA repair in cancer: emerging targets for personalized therapy

Abbotts

Thompson

Madhusudan

2014

CMAR

View full text Add to dashboard Cite

Genomic deoxyribonucleic acid (DNA) is under constant threat from endogenous and exogenous DNA damaging agents. Mammalian cells have evolved highly conserved DNA repair machinery to process DNA damage and maintain genomic integrity. Impaired DNA repair is a major driver for carcinogenesis and could promote aggressive cancer biology. Interestingly, in established tumors, DNA repair activity is required to counteract oxidative DNA damage that is prevalent in the tumor microenvironment. Emerging clinical data provide compelling evidence that overexpression of DNA repair factors may have prognostic and predictive significance in patients. More recently, DNA repair inhibition has emerged as a promising target for anticancer therapy. Synthetic lethality exploits intergene relationships where the loss of function of either of two related genes is nonlethal, but loss of both causes cell death. Exploiting this approach by targeting DNA repair has emerged as a promising strategy for personalized cancer therapy. In the current review, we focus on recent advances with a particular focus on synthetic lethality targeting in cancer.

show abstract

PISA, A novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situ

Cited by 2 publications

References 50 publications

DNA Repair and Chemotherapy

DNA Repair and Chemotherapy

DNA repair in cancer: emerging targets for personalized therapy

Contact Info

Product

Resources

About